Navigation Links
Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
Date:12/1/2008

MSI-1436 and two subjects in each dosing group will receive placebo. The multiple ascending dose protocol has an adaptive design permitting the enrollment of additional subjects in each cohort. Data from the study is expected in the first half of 2009.

MSI-1436 is also being evaluated in preclinical studies using a once-weekly subcutaneously administered formulation which Genaera expects to utilize in Phase 2 clinical trials in the second half of 2009.

About Trodusquemine (MSI-1436)

Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in Phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in Phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations a
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
11. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... is a hollow needle commonly used with a syringe ... extract fluids from it. A hypodermic needle is used ... that cannot be ingested. Hypodermic needles are broadly classified ...
(Date:7/11/2014)... -- On Thursday, July 10, 2014, ... Jones Industrial Average finished the day 0.42% lower at 16,915.07, ... losses were broad based as eight out of ten sectors ... Sector Index ended the day at 711.88, down 0.02%, while ... Investor-Edge has initiated coverage on the following equities: Covidien PLC ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Veran Medical Publishes Lung Cancer Patient Management Study 2
... OAK BROOK, Ill. , July 12 The University ... agreement to Ascent, a leader in health care resource sustainability. The agreement, ... 1, 2010 . Under the contract, Ascent will offer single-use device (SUD) ... , , , ...
... July 12 ( http://www.myprgenie.com ) -- Medrium, Inc., one ... announced it has signed a partnership agreement with RelayHealth to use ... LabCorp and to provide LabCorp results to physicians utilizing the Medrium ... , ...
Cached Medicine Technology:University HealthSystem Consortium Awards Single-Source Agreement to Ascent for Medical Device Reprocessing Services 2University HealthSystem Consortium Awards Single-Source Agreement to Ascent for Medical Device Reprocessing Services 3Medrium Partners With RelayHealth 2Medrium Partners With RelayHealth 3
(Date:7/13/2014)... editorial published today in The Lancet Neurology ... consideration the long term neurological problems that repeated ... most common form of sports-related traumatic brain injury ... may include dementia, amyotrophic lateral sclerosis, and other ... is perhaps more concerning, is that even when ...
(Date:7/13/2014)... identifies a novel genetic and molecular pathway ... opening up potential new therapeutic strategies for an ... is a chronic inflammatory disorder of the esophagus. ... certain foods and an over-accumulation in the esophagus ... the body,s immune system). EoE can cause a ...
(Date:7/13/2014)... July 13, 2014 The North American water ... in 2013 to $5,450 million by 2018, at a CAGR ... market is expanding at a rapid pace in North America. ... tightening laws on water & wastewater storage and collection, and ... The market is expanding at a healthy rate in Canada, ...
(Date:7/13/2014)... July 13, 2014 According to ... and Computing Market by Component (processor, GPU, DSP, ... MDA, Medical), and Geography - Forecast and Analysis ... Mobile Processing & Computing Market is expected to ... CAGR of 20.75% from 2014 to 2020. , ...
(Date:7/13/2014)... WA (PRWEB) July 13, 2014 Athletes ... longer recovery period from concussions, according to research presented ... ( AOSSM ) Annual Meeting. The research marks the ... concussion based on the known physical events that occur ... patients with a long allele in the (GT)n genotype ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... Programs for Eating Disorders,( http://www.remudaranch.com ), the nation,s ... surround the nation,s obsession,with dieting. As the dieting ... Americans continue to lose and gain weight in ... cycling may elevate blood pressure,reduce good cholesterol, deplete ...
... Medical Technologies,Inc., an innovator of endovascular treatments for ... another patent for its,Pathway PV(TM) Atherectomy System. The ... related to Pathway Medical,s innovative,atherectomy system, which is ... the legs. Pathway Medical has a total of ...
... women to enjoy casual sex just as men always had. ... the UK, the negative feelings reported by women after one-night ... sexual encounters. Her findings (1) are published online in ... , Men are more likely to reproduce and therefore to ...
... hurt. It was like [their father] had met some gal ... she wanted all his money. I felt they didn,t give ... still hurts.", --Remarried wife of 12 years, caring for husband ... Mich.---Late-life remarriage complicates caring for an ailing spouse, according to ...
... June 25 Hologic, Inc.,(Nasdaq: HOLX ) today ... the waiting period under the Hart-Scott-Rodino,Antitrust Improvements Act of ... in connection with Hologic,s previously announced tender offer for,all ... Third Wave,Technologies, Inc. (Nasdaq: TWTI ). The early ...
... looking for qualified candidates and tens of thousands of jobs being created ... graduates and despite the layoff announcements that tend to shock the average ... ... number of available jobs in health care continued to rise through the ...
Cached Medicine News:Health News:Leading Eating Disorder Treatment Center Identifies Popular Diet Myths 2Health News:Leading Eating Disorder Treatment Center Identifies Popular Diet Myths 3Health News:Was it good for you too? 2Health News:Late-life remarriage: Stepfamilies make caring more complex 2Health News:Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer 2Health News:The MedZilla Report: May 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: May 2008 Employment Outlook for Biotech/Pharma/Health 3
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... The Retinal Acuity Meter (RAM) is the ... to accurately predict RETINAL ACUITY in eyes with ... hand-held, battery operated, and can test each eye ... Optics, Inc. and tested at Columbia University in ...
... The Hoffmann® II Hybrid External Fixation ... next generation in hybrid fixation. It ... surgeons and is designed to offer ... exclusive patented Hoffmann® snap-fit technology. , ...
... add individual components for individual indications. XCaliber ... Made of an innovative composite plastic material, ... much lighter. This means it's easier to ... for the patient. ,Come pre-assembled, packaged sterile, ...
Medicine Products: